Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Zavod, Abigail [3 ]
Legedza, Anna [4 ]
Akerman, Sarah C. [5 ]
Sullivan, Maria A. [5 ,6 ]
机构
[1] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, 2213 Elba St,Ste 156,DUMC 3074, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Clin Res, Waltham, MA USA
[4] Alkermes Inc, Biostat, Waltham, MA USA
[5] Alkermes Inc, Med Affairs, Waltham, MA USA
[6] Columbia Univ, Dept Psychiat, New York, NY USA
来源
关键词
Antagonist; maintenance; opioid discontinuation; partial agonist; substance use; INPATIENT;
D O I
10.1080/00952990.2021.1969659
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Pharmacologic treatment is recommended for many individuals with opioid use disorder (OUD). For patients who select opioid antagonist treatment, effective management of opioid withdrawal symptoms during transition to antagonist treatment requires consideration of the patient experience. Objectives To compare patterns of opioid withdrawal between those withdrawing from untreated opioid use and those withdrawing from buprenorphine. Methods We performed a post hoc, cross-study comparison of the temporal pattern of opioid withdrawal during 1-week induction onto extended-release naltrexone by similar protocols enrolling two participant populations: participants with OUD entering a study with untreated opioid use (N = 378, NCT02537574) or on stable buprenorphine (BUP) treatment (N = 101, NCT02696434). Results The temporal pattern of withdrawal from induction day 1 through day 7 differed between the two participant populations for Clinical Opiate Withdrawal Score (COWS) and Subjective Opiate Withdrawal Score (SOWS): participants with untreated OUD prior to study entry were more likely to experience an earlier relative peak in opioid withdrawal followed by a gradual decline, whereas participants on stable BUP treatment prior to study entry were more likely to experience a relatively later, though still mild, peak opioid withdrawal. The peak COWS was reached at a mean (standard deviation) of 1.9 (1.5) days for participants with untreated OUD and 5.0 (1.5) days for participants on stable BUP. Daily peak cravings were generally higher for participants with untreated OUD than participants on stable BUP. Conclusion Awareness of population-specific variations in the patient experience of opioid withdrawal may help clinicians anticipate the expected course of withdrawal.
引用
收藏
页码:753 / 759
页数:7
相关论文
共 50 条
  • [1] Medications for OUD: Extended-Release Naltrexone
    Srivastava, A. Benjamin
    CURRENT ADDICTION REPORTS, 2025, 12 (01)
  • [2] Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency
    Wenzel, Kevin
    Fishman, Marc
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 120
  • [3] Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
    Ross, Rachael K.
    Nunes, Edward V.
    Olfson, Mark
    Shulman, Matisyahu
    Krawczyk, Noa
    Stuart, Elizabeth A.
    Rudolph, Kara E.
    ADDICTION, 2024, 119 (11) : 1975 - 1986
  • [4] ASSESSMENT OF TREATMENT PATHS FOR OPIOID USE DISORDER (OUD) PATIENTS AFTER AN ACUTE OUD EVENT
    Halpern, R.
    Mullen, W.
    Gaiazov, S.
    Le, L.
    Landis, C.
    Wheeler, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S83 - S83
  • [5] Use of Naltrexone in treating pregnant women with opioid use disorder (OUD)
    Towers, Craig V.
    Katz, Emily
    Visconti, Kevin
    Howard, Bobby
    Hennessy, Mark
    Fortner, Kimberly
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 220 (01) : S109 - S109
  • [6] Extended-release naltrexone for youth with opioid use disorder
    Mitchell, Shannon Gwin
    Monico, Laura B.
    Gryczynski, Jan
    Fishman, Marc J.
    O'Grady, Kevin E.
    Schwartz, Robert P.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 130
  • [7] Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period
    Galati, Bridget M.
    Wenzinger, Michael
    Rogers, Cynthia E.
    Cooke, Emily
    Kelly, Jeannie C.
    OBSTETRICS AND GYNECOLOGY, 2023, 142 (05): : 1148 - 1152
  • [8] Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians
    Randesi, Matthew
    Rotrosen, John
    Nunes, Edward, V
    Lee, Joshua D.
    Novo, Patricia
    Levran, Orna
    Ott, Jurg
    Pavlicova, Martina
    Scodes, Jennifer
    Kreek, Mary Jeanne
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2020, 46 (06): : 761 - 768
  • [9] Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting
    Mannelli, Paolo
    Douaihy, Antoine B.
    Akerman, Sarah C.
    Legedza, Anna
    Fratantonio, James
    Zavod, Abigail
    Sullivan, Maria A.
    AMERICAN JOURNAL ON ADDICTIONS, 2022, 31 (02): : 142 - 147
  • [10] Injectable Extended-Release Naltrexone Effective for Opioid Use Disorder
    Slawson, David C.
    AMERICAN FAMILY PHYSICIAN, 2018, 97 (12) : 819 - 819